MedTrace Logo

Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

NCT00250874 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2005-11-08

No results posted yet for this study

Summary

To study the pharmacokinetic profile of the therapeutic schedule in order to demonstrate absence of negative interactions among the 3 drugs administered

Conditions

Interventions

DRUG

Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab

Sponsors & Collaborators

  • Zeneus Pharma

    lead INDUSTRY

Principal Investigators

  • Professor Amadori · Ospedale Pietrantoni, Forli, Italy

  • Professor Gasparini · San Filippo Neri, Rome, Italy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00250874 on ClinicalTrials.gov